According to a recent article, the biopharmaceutical company Amryt has announced a study looking at Mycapssa to treat patients with carcinoid symptoms as a result of neuroendocrine tumors (NET). Neuroendocrine…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
CURE® recently conducted an interview with von Hippel-Lindau (VHL) patient Joseph Heisler and his mother, Marirene. Joseph’s father was diagnosed thirty years ago with the genetic (inherited) disease. Shortly thereafter…
Unfortunately, a pancreatic cancer diagnosis also comes with a poor prognosis. Since many people do not receive a diagnosis until later stages of the cancer, the 5-year survival rate is…
According to a recent article, a new study shows a daily oral dose of Belzutifan may keep patients diagnosed with von Hippel-Lindau disease from needing surgery by shrinking tumors. Von…
Pancreatic cancer can present numerous problems for medical professionals. To start, this cancer can be difficult to detect and diagnose in early stages. By the time pancreatic cancer progresses,…
A recent article highlighted the fact that November is carcinoid cancer month and is helping spread awareness about the disease in the hopes of earlier diagnosis. Carcinoid Syndrome Carcinoid syndrome…
Years ago, talabostat (BXCL701) failed during a Phase 3 clinical trial to evaluate the therapy for patients with pancreatic cancer. However, drug developer BioXcel Therapeutics (“BioXcel”) did not give up…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
